Best Pharma Stocks in August: Neuland, Laurus Labs, Sun Pharma And More- Based on 5-Year CAGR

The Indian pharma industry plays a key role in global healthcare, contributing 50% of global vaccine supply, 40% of the generic drugs used in the U.S., and 25% of those in the U.K. Within the country, the sector includes around 3,000 pharmaceutical firms and 10,500 manufacturing units, contributing about 1.72% to India’s GDP.

Let’s now explore the top-performing Indian pharmaceutical stocks for August 2025, based on their 5-year CAGR, net profit margin, and market capitalisation.

Best Pharma Stocks in India in August 2025 – 5yr CAGR Basis

Note: The list of top pharma stocks in India in August here is picked from the Nifty 500 universe and is sorted as per 5-year CAGR as of July 30, 2025. 

Overview of Best Pharma Stocks in India in August 2025

1. Neuland Laboratories

Neuland Laboratories is involved in the production and sale of active pharmaceutical ingredients (APIs), serving both Indian and global markets.

For FY 2024-25, Neuland Laboratories reported a total income of ₹1,497.35 crore, with quarterly income of ₹335.82 crore in March 2025, ₹401.94 crore in December 2024, ₹315.18 crore in September 2024, and ₹444.41 crore in June 2024. 

Key Metrics: 

• Earning per share (EPS): ₹202.20
• Return on equity (ROE): 18.68%

2. Laurus Labs

Established in 2005, Laurus Labs is a pharmaceutical and biotechnology company with a strong focus on research. It is globally recognized for producing essential Active Pharmaceutical Ingredients (APIs), especially in therapeutic areas such as anti-retroviral, oncology, cardiovascular, gastroenterology, and high-potency APIs.

For the quarter ended June 2025, Laurus Labs reported revenue of ₹1,432.75 crore and a net profit of ₹157.94 crore. In the previous quarter, March 2025, the company posted revenue of ₹1,650.01 crore and a net profit of ₹251.90 crore. 

Key metrics: 

• EPS: ₹11.44
• ROE: 11.93%

3. Caplin Point Laboratories

Caplin Point Laboratories Ltd focuses on producing and sourcing Active Pharmaceutical Ingredients (APIs) and finished dosage formulations. The company is also active in research and development (R&D) and clinical trials, maintaining a strong footprint in Latin America, Africa, the USA, and various other international markets.

For the quarter ended March 2025, Caplin Point Laboratories Ltd reported a revenue of ₹173.61 crore and a net profit of ₹86.50 crore. In the previous quarter, December 2024, the company recorded ₹185.23 crore in revenue and ₹74.71 crore in net profit. 

Key metrics: 

• EPS: ₹44.66
• ROE: 22.12%

4. J.B. Chemicals and Pharmaceuticals

Established in 1976, J.B. Chemicals and Pharmaceuticals Limited (JBCPL) is a prominent Indian pharmaceutical company. It is a publicly listed, fully integrated firm known for delivering high-quality, affordable medicines across India and international markets. JBCPL is widely trusted by healthcare professionals around the world.

For the quarter ended March 2025, J.B. Chemicals and Pharmaceuticals Limited reported revenue of ₹901.34 crore and a net profit of ₹149.80 crore. In the previous quarter ending December 2024, revenue stood at ₹913.51 crore with a net profit of ₹156.39 crore. 

Key metrics: 

• EPS: ₹41.81
• ROE: 20.67%

5. Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd is a global pharmaceutical company driven by research, operating in more than 80 countries. It is active in the generics, speciality, and over-the-counter (OTC) segments.

For the quarter ended March 2025, Glenmark Pharmaceuticals reported a revenue of ₹2,009.49 crore and a net profit of ₹147.76 crore. In the December 2024 quarter, revenue stood at ₹2,251.28 crore with a net profit of ₹413.80 crore.

Key metrics: 

• EPS: ₹57.06
• ROE: 6.72%

Read More: Best Oil and Gas Stocks in India in August 2025- Oil India, ONGC, and Others Based on 5Y CAGR!

Best Pharma Stocks in India in August 2025 – Market Cap Basis

Note: The list of top pharma stocks in India in August here is picked from the Nifty 500 universe and is sorted as per market cap as of July 30, 2025. 

Best Pharma Stocks in India in August 2025 – Net Profit Margin

Note: The list of top pharma stocks in India in August here is picked from the Nifty 500 universe and is sorted as per net profit margin as of July 30, 2025. 

Key Things to Consider Before Investing in Pharma Stocks in India

Healthcare Infrastructure Growth

The expansion of hospitals, clinics, and medical facilities in India directly influences the growth of the pharmaceutical sector. As healthcare access improves, the demand for medicines increases, creating more opportunities for pharma companies to grow.

Increasing Demand for Medicines

Factors like a growing elderly population, higher healthcare spending, and the rise in lifestyle and infectious diseases are driving medicine demand. Investors should evaluate both current needs and future healthcare trends to judge the long-term potential of pharmaceutical stocks.

Industry Competition and Market Changes

India’s pharma sector is highly competitive, with many companies entering into mergers and acquisitions to strengthen their position. Before investing, it’s important to review a company's market share, recent performance, and future growth plans.

Emphasis on Research and Development

Pharma firms often invest heavily in research to develop new drugs. Looking into how much a company spends on R&D and its upcoming product pipeline can offer a better understanding of its innovation capabilities and future earnings.

Conclusion

India’s pharmaceutical industry offers promising investment opportunities due to its strong global presence. However, investors should be mindful of potential risks such as regulatory changes, especially those affecting prices and exports. Dependence on international markets, particularly the US, also exposes companies to the impact of FDA inspections and policy shifts. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.